Phoebe opens new urgent care clinic in Camilla
CAMILLA — Phoebe Putney Health System has expanded its network of urgent care clinics by opening a new location in Camilla. The facility will provide residents in Camilla and surrounding areas with convenient access to high-quality, prompt medical care.
Phoebe officials and community leaders took part in a ribbon-cutting ceremony Monday afternoon to commemorate the milestone.
'The opening of Phoebe Urgent Care in Camilla represents our commitment to expanding access to exceptional health care services across our communities,' Phoebe Putney Health System President and CEO Scott Steiner said. 'This milestone is a testament to the hard work and dedication of our team, and we look forward to continuing to serve our neighbors with compassion and care.'
Phoebe Urgent Care is committed to delivering safe, in-person care for non-life-threatening illnesses and injuries, catering to patients of all ages, from pediatrics to geriatrics. A skilled team of physicians, nurse practitioners, and physician assistants at Phoebe Urgent Care treat a variety of conditions, including but not limited to:
– Asthma and allergies
– Cuts requiring minor stitching
– Minor broken bones and simple fractures
– Respiratory illnesses such as flu, strep throat, COVID-19, and RSV
'With the opening of our new urgent care center in Camilla, we are reinforcing Phoebe's mission to provide accessible, high-quality health care to families and individuals across southwest Georgia,' Phoebe Physicians President Dr. Estrellita Redmon said. 'This new location reflects our commitment to serving communities where the need is greatest.'
The Camilla location joins Phoebe's growing network of urgent care clinics across the region, including Phoebe Urgent Care of East Albany, Phoebe Urgent Care of Lee County, Phoebe Urgent Care North Campus and Phoebe Urgent Care at Northwest Albany. Phoebe plans to further expand in Lee County with a new urgent care facility on U.S. Highway 82 later this year. Renovations are wrapping up at Phoebe East, with renovations and expansions planned at Phoebe North and Phoebe Northwest. Phoebe Urgent Care prioritizes access, quality and innovation, offering same-day testing, limited labs and telehealth options.
Telehealth provides convenient, remote access to medical services, ensuring timely and expert care for certain patients who may be unable to make it to an in-person appointment. Phoebe Urgent Care Telehealth operates from 7:30 a.m. to 4:30 p.m.
'The opening of Phoebe Urgent Care in Camilla brings comprehensive health care closer to home for more southwest Georgians,' Martavius Marcus, the director of Physician Practices at Phoebe Physician Group, said. 'For those who may not have an urgent care location nearby or find it challenging to visit in person, our telehealth services offer a seamless alternative. Patients can schedule appointments and receive expert medical care from the comfort of their homes, ensuring that exceptional health care is always accessible, no matter where they reside.'
The new Camilla clinic is located in the same building as Phoebe Primary Care of Camilla at 725 U.S. Highway 19 South. For more information about Phoebe Urgent Care and/or Phoebe Telehealth, visit www.phoebehealth.com/urgentcare.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that's the No. 1 cause of hospitalization in infants. The US Food and Drug Administration has approved a new monoclonal antibody to help prevent infection, according to an announcement late Monday from drugmaker Merck. The therapy, Enflonsia, is designed to be given in a single 105-milligram shot to protect newborns and infants from mild, moderate or severe RSV through all five months of their first virus season, which typically starts in the fall and goes through the next spring. Study materials that Merck submitted to the FDA for its approval showed that the antibody had a similar safety profile as a placebo. The most common adverse reactions from Enflonsia were mild and included injection-site swelling and a rash in a small number of infants. In a mid- to late-stage trial, Enflonsia reduced RSV-associated hospitalizations in infants more than 84% compared with a placebo. RSV can sometimes turn into serious lower respiratory infections like pneumonia, but the shot also reduced lower respiratory infections that needed medical attention by more than 60% compared with a placebo. 'Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season,' Dr. Dean Y. Li, president of Merck Research Laboratories, said in a news release. 'We are committed to ensuring availability of Enflonsia in the US before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems.' Merck says it hopes Enflonsia will be available before the start of the 2025-26 respiratory virus season. First, it needs to be recommended by the US Centers for Disease Control and Prevention, and that means going in front of the agency's Advisory Committee on Immunization Practices. It's on the agenda for the panel's meeting this month, but US Health and Human Services Secretary Robert F. Kennedy removed all the members of that committee Monday. He says he will appoint new ones, but it's unclear how long that process will take. Doctors say another tool to prevent RSV cannot come soon enough. RSV is ubiquitous, one of the most common causes of childhood illness. Most kids will catch this highly contagious respiratory virus at some point before they turn 2, according to the CDC. For many healthy adults and older kids, RSV causes a mild illness like a cold. Typically, symptoms can be managed at home, and they often go away on their own. But for infants and the elderly, it can be a different story. Very young children's immune systems are just starting to learn how to fight infections, and infants have tiny airways. RSV inflames those airways, making it difficult to breathe, and can turn into a serious lower respiratory illness like bronchiolitis or pneumonia. Some of these RSV infections can be deadly. Two to three percent of infants under 6 months are hospitalized with RSV in the US every year, according to the CDC. Among children younger than 5, about 58,000 to 80,000 are hospitalized due to RSV. There's no specific medicine to treat RSV. Doctors can give an infant supportive care and oxygen, and then they essentially wait until their oxygen levels get back to normal, said Dr. Amy Edwards, director of pediatric infection control at UH Rainbow Babies and Children's Hospital in Cleveland. 'I hate RSV,' said Edwards, who was not connected with the Merck trial. 'Just to watch them struggle to breathe, and then they get scared, and then they cry, which of course makes the breathing worse, and their little lips turn blue. It's just so hard to watch.' Enflonsia joins a handful of other tools recently made available to protect babies from, although the FDA put RSV vaccine trials involving infants and young children ages 2 to 5 on hold last year after some developed severe illness. To prevent RSV in infants, the CDC currently recommends an RSV antibody made by Sanofi and AstraZeneca, called Beyfortus, which was approved in 2023. It was in short supply during that year's RSV season, although Edwards said supply started to catch up with demand in her health care system last season, and the company pledged to produce more. The other option to protect an infant is a vaccine that a person can get during pregnancy. Together, Beyfortus and the vaccine have made a difference. A CDC study published in March found that RSV-associated hospitalization rates among infants up to 7 months during 2024-25 season were lower than in seasons when those therapies weren't available. Edwards just hopes people will get protection for their infants. 'Every RSV season fills us to the gills,' she said. 'This should theoretically empty us out, if we have good uptake.'
WebMD
4 hours ago
- WebMD
FDA OKs New Shot to Protect Babies Against RSV
June 10, 2025 – The FDA has approved a new shot to prevent respiratory syncytial virus (RSV) infection in babies during their first RSV season, which typically lasts from fall through spring. Clesrovimab, which is sold as Enflonsia, is the first and only RSV protection for babies that uses the same dose for all infants, regardless of their body weight. This makes it a simpler and more precise option that ensures reliable protection throughout the RSV season. RSV is a common virus that spreads during colder months through coughs, sneezes, direct contact, or contaminated surfaces. It typically causes mild, cold-like symptoms. Infants (especially those under 6 months) and older adults are more likely to have a severe RSV infection. RSV can cause bronchiolitis (inflammation of small airways) and pneumonia, sometimes leading to hospitalization. Because it's the leading cause of hospitalization in infants, vaccines and preventive treatments are the best way to protect them. Merck, the maker of the new preventive, said the FDA's decision was based on two clinical trials. In the first trial, a single dose of Enflonsia was given to newborns, both preterm and full-term, and reduced RSV severe lung infections by 60% and hospitalizations by 84% over five months, compared to a placebo. The second trial showed Enflonsia was as effective and safe as an older RSV medicine (palivizumab) for babies at higher risk, such as those born very early or with lung or heart issues. The clinical trials also showed that Enflonsia was just as safe on its own or with other routine childhood vaccines. "Enflonsia combines dosing convenience with strong clinical data showing significant reductions in RSV disease incidence and hospitalizations, making it a promising new intervention to help protect infants from RSV," Octavio Ramilo, MD, chair of the Department of Infectious Diseases at St. Jude Children's Research Hospital and investigator for the clinical trials, said in a statement. The Enflonsia shot contains ready-made antibodies that help newborns and infants fight off RSV before it can cause serious lung infections. It uses a single, non-weight-based, 105-mg dose that gives fast and lasting protection for about five months. Babies born during RSV season should get the shot at birth, while those born before the season should get it just before it starts. The preventive is given as an injection in the baby's thigh.
Scientific American
4 hours ago
- Scientific American
How RFK, Jr.'s Dismissal of CDC Immunization Committee Panelists Will Affect America's Vaccine Access
In a striking move on Monday, Robert F. Kennedy, Jr., secretary of the U.S. Department Health and Human Services, announced the dismissal of all sitting public health experts of an independent vaccine committee that counsels the U.S. Centers for Disease Control and Prevention. Called the Advisory Committee on Immunization Practices, or ACIP, the group holds public meetings to review the latest scientific evidence on vaccine safety and effectiveness and to make clinical recommendations for people in the U.S.—guidance that greatly influences access to disease-preventing shots. In his announcement in a Wall Street Journal op-ed, Kennedy— who has a long history of as an antivaccine activist —framed the firings as taking 'a bold step in restoring public trust by totally reconstituting the Advisory Committee for Immunization Practices.' He also alleged there were 'persistent conflicts of interest' among committee members. Public health experts had been bracing for such a move. 'This was everybody's fear about having RFK, Jr., as our HHS secretary,' says Jennifer Nuzzo, an epidemiologist and director of the Pandemic Center at Brown University. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. ACIP's decisions shape immunization schedules —affecting which groups will be recommended vaccines, when and how often they should get them and whether health insurance will cover costs. The panelists hold three open meetings each year to assess and vote on the clinical use of various existing and new vaccines, including ones that protect people against pneumonia, chicken pox, shingles, measles, mumps and rubella (MMR), polio, respiratory syncytial virus (RSV), influenza and COVID. According to the agenda of ACIP's next meeting, slated for June 25–27, members are expected to vote on highly anticipated recommendations that would influence the next winter respiratory illness season—including guidance for COVID, flu and RSV vaccines for adults and children. In response to various questions about the plans for ACIP, an HHS spokesperson directed Scientific American to the agency's statement about the announcement and said the committee is still scheduled to meet on June 25–27. According to the statement, new committee members are currently under consideration. The secretary of health and human services gives the final approval of newly appointed ACIP members. 'I cannot imagine that they could compose a new ACIP that has been sufficiently vetted in [less than] three weeks,' Nuzzo says. 'One of the reasons why there's so much concern right now is that changing the composition of ACIP, potentially stacking it with antivaccine members, as many fear could happen, could make it harder for Americans to access vaccines that they want, that their doctors think are beneficial for them.' Scientific American spoke with Nuzzo about how the ACIP dismissal may affect vaccine policy and access and people's health. [ An edited transcript of the interview follows. ] What is the primary role of ACIP? There are a few features of the committee that make it important. One is expertise. The membership of the committee is somewhat diverse to represent a range of expert backgrounds because when you're talking about vaccines, there are pediatric issues, adult issues—a lot of different types of expertise need to be brought to bear. It's also an independent group, meaning that it's not populated by any particular political party. ACIP's members are outside experts who are appointed through a very transparent, open process, up to a fixed term. These are independent, nonpolitical actors who also have their conflicts of interests managed. Who they get money from is public knowledge. [ Editor's Note: Members withdraw themselves from deliberations and voting on any product for which they have disclosed a conflict of interest. ] How does ACIP make its decisions? During the meeting, [the members] have documents, they have people giving presentations. Sometimes those presentations are given by government scientists who have reviewed evidence, or sometimes [the members will look at] evidence from studies on vaccines. All of the meetings are open: either you could show up in public or, usually, [see a] broadcast on the web. So all of the data that are used in the discussion about vaccines and vaccine policies are made public, and they are reviewed. And not only are they reviewed, but the rationale and the interpretation of those data are public. So the public can see, interrogate, and vet the conclusions and the data that the committees use to base their conclusions. It's a very open [process], and that openness adheres to a governance structure has existed throughout multiple presidential administrations, multiple political parties presiding [over] it. It's also important to note that the CDC director does not have to accept ACIP's recommendations—the CDC director usually does, but the CDC director does not have to. My worry is not just that politics enters into ACIP; it's also just that 'Will the will of ACIP be adhered to?' How do ACIP's recommendations affect people? ACIP is one of two key advisory committees that serve the U.S. government related to vaccines [the other is the Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee (VRBPAC) ]. ACIP makes recommendations regarding vaccine policies and utilization—and those recommendations are important, not just because they represent the scientific consensus that exists at the time but also because they usually influence people's access to vaccines. One real concern is: if ACIP doesn't recommend a vaccine, insurers may decide not to cover the cost , and some of these vaccines have important out-of-pocket costs. Some of us can afford that, but a lot of us can't. And so there are real issues about who is going to be able to benefit from vaccines, and it creates a real inequity. It may also have an effect on the market and companies' willingness to incur the risks of making vaccines. Vaccines are not like making a car. There are a discovery process and research-and-development process that have to occur. If vaccine manufacturers fear that they're not going to be able to sell vaccines, that people aren't going to be able to access them, then they may simply decide not to make them. They might decide that the U.S. market is not where they want to invest their resources and may decide to instead serve other countries. So it's not just that ACIP provides advice that the American public can use to make their own vaccine decisions but also [that it] is often the basis by which [vaccine] providers and insurers make vaccines available. So it's not just about information; it's also about access. What does this action potentially mean for future vaccine policies? I'm worried about all vaccines at this point. I can't rule out that that isn't just the first warning shot. Some of the rationale around who should or should not get COVID boosters, in my view, feels like an opening to removing the availability of flu vaccines. We've seen the secretary of HHS wrongly malign MMR vaccines amid one of the worst measles outbreaks the U.S. has seen in decades. So I fear that everything's fair game.
